TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced updated clinical data from its Phase 1a dose-escalation trial of TTX-MC138, an anti-miR-10b therapeutic candidate, on September 28, 2026. The data cutoff date for this report was September 1, 2026.
As of the data cutoff, 14 patients were efficacy-evaluable. The reported stable disease rate was 71.4%, with a disease control rate of 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. The durability of responses was noted, with six patients progression-free at three months, three at six months, and three at both nine and twelve months.
TransCode reported that the primary safety endpoint was met. No dose-limiting toxicities were observed across evaluated dose levels, including the highest dose of 4.8 mg/kg. Additionally, administration of the drug for over a year was well tolerated.
Post-hoc analysis using the Growth Modulation Index (GMI) indicated that 40% of evaluable patients achieved a GMI greater than 1.3, suggesting a 30% longer progression-free interval compared to the patient's most recent prior therapy. Exploratory RNA-sequencing analysis identified treatment-associated immune activation, including increases in antitumor cytokines and cytotoxic effector activity.
